Reaction
Transplant Evaluation reporting signals
As of the last recalculation, Transplant Evaluation appears in 504 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is EPOPROSTENOL (PRR 507.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Epoprostenol | 122 | 507.5 | 512.3 |
| Macitentan | 149 | 125.7 | 126.0 |
| Selexipag | 56 | 100.6 | 100.8 |
| Riociguat | 67 | 97.7 | 97.9 |
| Sildenafil Powder, | 68 | 91.1 | 91.2 |
| Sildenafil | 94 | 82.1 | 82.3 |
| Tadalafil | 115 | 61.2 | 61.2 |
| Ambrisentan | 133 | 59.4 | 59.5 |
| Sildenafil Citrate | 123 | 52.5 | 52.5 |
| Bosentan | 54 | 49.4 | 49.5 |
| Treprostinil | 114 | 48.2 | 48.2 |
| Blinatumomab | 9 | 36.3 | 36.3 |
| 0Xygen | 37 | 33.4 | 33.4 |
| Oxygen | 37 | 33.4 | 33.4 |
| Rifaximin | 9 | 18.0 | 18.1 |